Drug development provider Icon PLC (Nasdaq: ICLR) saw its stock jump about 6% in value today after announcing second-quarter earnings that beat analysts’ expectations.
The Dublin, Ireland–based company, which serves the pharmaceutical, biotechnology and medical device industries, also said it has acquired the Mapi Group, which provides patient-centered health outcomes research and commercialisation. Financial terms of the deal were not disclosed.
For the quarter ended June 30, Icon earned $64.8 million, or $1.19 per share, off $431.0 million in revenue – up from earnings of $61.1 million, or $1.08 per share, off $410.6 million in revenue during the same quarter a year ago.
Minus non-recurring charges, Icon earned $1.31 per share during the second quarter, beating analysts’ consensus by a penny. Revenue was also above the $430.85 million predicted by analysts polled on Yahoo! Finance.